IL256032D0 - Substituted pyridines and method of use - Google Patents

Substituted pyridines and method of use

Info

Publication number
IL256032D0
IL256032D0 IL256032A IL25603217A IL256032D0 IL 256032 D0 IL256032 D0 IL 256032D0 IL 256032 A IL256032 A IL 256032A IL 25603217 A IL25603217 A IL 25603217A IL 256032 D0 IL256032 D0 IL 256032D0
Authority
IL
Israel
Prior art keywords
use
method
substituted pyridines
pyridines
substituted
Prior art date
Application number
IL256032A
Other languages
Hebrew (he)
Inventor
Robert J Altenbach
Marlon D Cowart
Munck Tom Roger Lisette De
Montovert Sebastien Jean Jacques Cedric Dropsit
Gregory A Gfesser
Hans Kelgtermans
Sebastien Laurent Xavier Martina
Der Plas Steven Emiel Van
Xueqing Wang
Original Assignee
Galapagos Nv
Abbvie S A R L
Robert J Altenbach
Marlon D Cowart
Munck Tom Roger Lisette De
Montovert Sebastien Jean Jacques Cedric Dropsit
Gregory A Gfesser
Hans Kelgtermans
Sebastien Laurent Xavier Martina
Der Plas Steven Emiel Van
Xueqing Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201562169881P priority Critical
Priority to PCT/IB2016/000821 priority patent/WO2016193812A1/en
Application filed by Galapagos Nv, Abbvie S A R L, Robert J Altenbach, Marlon D Cowart, Munck Tom Roger Lisette De, Montovert Sebastien Jean Jacques Cedric Dropsit, Gregory A Gfesser, Hans Kelgtermans, Sebastien Laurent Xavier Martina, Der Plas Steven Emiel Van, Xueqing Wang filed Critical Galapagos Nv
Publication of IL256032D0 publication Critical patent/IL256032D0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with heteroatoms or with carbon atoms having three bonds to hetero atoms, with at the most one to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
IL256032A 2015-06-02 2017-11-30 Substituted pyridines and method of use IL256032D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US201562169881P true 2015-06-02 2015-06-02
PCT/IB2016/000821 WO2016193812A1 (en) 2015-06-02 2016-05-25 Substituted pyridines and method of use

Publications (1)

Publication Number Publication Date
IL256032D0 true IL256032D0 (en) 2018-01-31

Family

ID=57440295

Family Applications (1)

Application Number Title Priority Date Filing Date
IL256032A IL256032D0 (en) 2015-06-02 2017-11-30 Substituted pyridines and method of use

Country Status (21)

Country Link
US (1) US10047051B2 (en)
EP (1) EP3303294A1 (en)
JP (1) JP2018516932A (en)
KR (1) KR20180029204A (en)
CN (1) CN107922338A (en)
AR (1) AR106865A1 (en)
AU (1) AU2016272702A1 (en)
BR (1) BR112017026132A2 (en)
CA (1) CA2988046A1 (en)
CL (1) CL2017003067A1 (en)
CO (1) CO2017012566A2 (en)
CR (1) CR20170595A (en)
DO (1) DOP2017000278A (en)
IL (1) IL256032D0 (en)
MX (1) MX2017015591A (en)
PE (1) PE4572018A1 (en)
PH (1) PH12017502201A1 (en)
RU (1) RU2017146661A (en)
TW (1) TW201713621A (en)
UY (1) UY36702A (en)
WO (1) WO2016193812A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10138227B2 (en) 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
TW201811766A (en) 2016-08-29 2018-04-01 瑞士商諾華公司 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease
US10399940B2 (en) 2016-10-07 2019-09-03 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
US9981910B2 (en) 2016-10-07 2018-05-29 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
EP3558982A1 (en) 2016-12-20 2019-10-30 AbbVie S.À.R.L. Deuterated cftr modulators and methods of use
TW201831471A (en) 2017-02-24 2018-09-01 盧森堡商艾伯維公司 Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
US20190077784A1 (en) 2017-09-14 2019-03-14 AbbVie S.à.r.l. Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
WO2019193062A1 (en) 2018-04-03 2019-10-10 Abbvie S.Á.R.L Substituted pyrrolidines and their use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939558B2 (en) 2004-06-04 2011-05-10 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
RS56873B1 (en) 2004-06-24 2018-04-30 Vertex Pharma Modulators of atp-binding cassette transporters
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
EP2170901B1 (en) 2007-05-25 2015-07-01 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CA2707857C (en) 2007-12-10 2016-09-13 Novartis Ag Spirocyclic amiloride analogues
CN101925603B (en) 2007-12-13 2013-12-04 沃泰克斯药物股份有限公司 Modulators of cystic fibrosis transmembrane conductance regulator
ES2406361T3 (en) 2008-10-23 2013-06-06 Vertex Pharmaceuticals Incorporated Solid forms of N- (4- (7-azabicyclo [2.2.1] heptan-7-yl) -2- (trifluoromethyl) phenyl) -4-oxo-5- (trifluoromethyl) -1,4-dihydroquinolin-3 -carboxamide
US8367660B2 (en) 2008-12-30 2013-02-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US8247436B2 (en) * 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
US9034879B2 (en) 2011-09-16 2015-05-19 Novartis Ag Heterocyclic compounds for the treatment of CF
EP2755652A1 (en) 2011-09-16 2014-07-23 Novartis AG N-substituted heterocyclyl carboxamides
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
DK2760463T3 (en) 2011-09-20 2019-03-18 Univ North Carolina Chapel Hill Regulation of sodium channels using plunc proteins
WO2014180562A1 (en) 2013-05-07 2014-11-13 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
MX2016001602A (en) 2013-08-08 2016-12-15 Galapagos Nv Thieno[2,3-c]pyrans as cftr modulators.
CA2942386A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
WO2015138934A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity

Also Published As

Publication number Publication date
CR20170595A (en) 2018-04-27
PH12017502201A1 (en) 2018-06-11
MX2017015591A (en) 2018-04-30
AU2016272702A1 (en) 2017-12-21
EP3303294A1 (en) 2018-04-11
US10047051B2 (en) 2018-08-14
CA2988046A1 (en) 2016-12-08
JP2018516932A (en) 2018-06-28
CN107922338A (en) 2018-04-17
US20160355480A1 (en) 2016-12-08
UY36702A (en) 2016-12-30
WO2016193812A1 (en) 2016-12-08
DOP2017000278A (en) 2018-01-15
CO2017012566A2 (en) 2018-03-09
AR106865A1 (en) 2018-02-28
PE4572018A1 (en) 2018-03-05
TW201713621A (en) 2017-04-16
KR20180029204A (en) 2018-03-20
CL2017003067A1 (en) 2018-06-01
RU2017146661A (en) 2019-07-15
BR112017026132A2 (en) 2018-08-28

Similar Documents

Publication Publication Date Title
IL251868D0 (en) Anti-tim3 antibodies and methods of use
IL257216D0 (en) Pd-1-binding molecules and methods of use thereof
IL251821D0 (en) Cannabis extracts and methods of preparing and using same
IL257636D0 (en) Anti-tigit antibodies and methods of use
SG11201803583TA (en) Apparatuses and methods including memory and operation of same
IL251996D0 (en) Substituted chromanes and method of use
GB2526633B (en) Garment and method of manufacturing same
GB201512955D0 (en) Receiver and method of receiving
SG11201606575TA (en) Method of producing polyethylene and polyethylene thereof
EP3212184A4 (en) Substituted tetrahydropyrans and method of use
IL256179D0 (en) Lag-3-binding molecules and methods of use thereof
HUE039940T2 (en) Anti-jagged1 antibodies and methods of use
IL255830D0 (en) Bicyclic lactams and methods of use thereof
IL256376D0 (en) Factor xi antibodies and methods of use
IL256250D0 (en) Hpk1 inhibitors and methods of using same
RU2017101339A (en) Exoskeleton and method of its use
SG11201706583PA (en) Anti-pvrig antibodies and methods of use
EP3429635A4 (en) Anti-crispr compounds and methods of use
RU2015126469A (en) Electronic equipment and method of its use
GB2541823B (en) Security elements and methods of their manufacture
GB201509463D0 (en) Improved apparatus and method
SG11201708220RA (en) Anti-sortilin antibodies and methods of use thereof
ZA201700217B (en) Antiproliferative compounds and methods of use thereof
SG11201606274XA (en) Anti-mcam antibodies and associated methods of use
GB201416835D0 (en) Apparatus and method of user interaction